Research Article
Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis
Table 1
Baseline demographic characteristics.
| | Characteristic | Treatment-naive
() | Previously treated
() | Total
() |
| | Mean age, years | 56.5 | 54.3 | 55.9 | | Mean BMI, kg/ | 26.44 | 26.98 | 26.59 | | Sex | | | | | Male, (%) | 308 (54.2) | 120 (57.4) | 428 (55.1) | | Female, (%) | 260 (45.8) | 89 (42.6) | 349 (44.9) | | Race | | | | | White, (%) | 420 (73.9) | 198 (94.7) | 618 (79.5) | | Nonwhite (%) | 148 (26.1) | 11 (5.3) | 159 (20.5) | | Fibrosis stage | | | | | Metavir F0–F2 | 330 (58.1) | 100 (47.8) | 430 (55.3) | | Metavir F3 | 46 (8.1) | 27 (12.9) | 73 (9.4) | | Metavir F4 | 192 (33.8) | 82 (39.2) | 274 (35.3) | | HCV genotype, (%) | | | | | 1a | 326 (57.4) | 106 (50.7) | 432 (55.6) | | 1b | 209 (36.8) | 103 (49.3) | 312 (40.2) | | 1-other | 33 (5.8) | 0 | 33 (4.2) | | Mean HCV RNA, log10 (IU/mL) | 6.39 | 6.49 | 6.42 | | IL28B CC genotype, (%) | | | | | CC | 172 (97.7) | 4 (2.3) | 176 (22.7) | | Non-CC | 393 (66.5) | 198 (33.5) | 591 (76.1) | | Unknown | 3 (30.0) | 7 (70.0) | 10 (1.3) | | Regimen received | | | | | GZR-EBR 12 weeks | 389 (68.5) | 33 (15.8) | 422 (54.3) | | GZR-EBR + RBV 12 weeks | 116 (20.4) | 111 (53.1) | 227 (29.2) | | GZR-EBR 18 weeks | 31 (5.5) | 32 (15.3) | 63 (8.1) | | GZR-EBR + RBV 18 weeks | 32 (5.6) | 33 (15.8) | 65 (8.4) |
|
|
